Tag: EGFR-HER3 bispecific ADC

At the annual meeting of the American Association for Cancer Research (AACR), held April 17 - 22, 2026, in San Diego, CA., new preclinical data will be presented for three proprietary antibody-drug conjugate (ADC) assets—CS5007 (EGFR/HER3 ADC), CS5006 (ITGB4 ADC), and CS5008 (DLL3/SSTR2 ADC)—being developed by CStone Pharmaceuticals.

Updated safety & efficacy data from a phase 1 clinical study evaluating BL-B01D1 (SystImmune; see Drugmap), a bispecific topoisomerase inhibitor-based antibody-drug conjugates that targets both epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3) in locally advanced or metastatic breast cancer patients will be presented in a poster at the San Antonio Breast Cancer Symposium (SABCS) 2024, taking place on December 10-13 in San Antonio, Texas.